LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Simulations Plus Inc

Suletud

SektorTervishoid

15.92 -0.62

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

15.44

Max

16.38

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

4.5M

Müük

5.9M

24M

Aktsiakasum

0.35

Kasumimarginaal

18.669

Töötajad

212

EBITDA

4.9M

7.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-0.06% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

70M

321M

Eelmine avamishind

16.54

Eelmine sulgemishind

15.92

Uudiste sentiment

By Acuity

95%

5%

319 / 344 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuni 2026, 23:36 UTC

Tulu

Correction to Oracle Reports Higher 4Q Profit Article

10. juuni 2026, 23:19 UTC

Kuumad aktsiad

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10. juuni 2026, 23:09 UTC

Suurimad hinnamuutused turgudel

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10. juuni 2026, 23:04 UTC

Tulu

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10. juuni 2026, 20:44 UTC

Suurimad hinnamuutused turgudel

Caterpillar Raises Quarterly Dividend 8%

10. juuni 2026, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Should Take No Options Off The Table

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10. juuni 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10. juuni 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10. juuni 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10. juuni 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10. juuni 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. juuni 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10. juuni 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10. juuni 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10. juuni 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10. juuni 2026, 21:57 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 21:52 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 21:35 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 21:22 UTC

Tulu

Oracle Stock Slides on Increased Capital Spending -- WSJ

10. juuni 2026, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

10. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. juuni 2026, 20:39 UTC

Market Talk
Tulu

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10. juuni 2026, 20:34 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10. juuni 2026, 20:33 UTC

Tulu

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

-0.06% langus

12 kuu keskmine prognoos

Keskmine 16 USD  -0.06%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

319 / 344 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat